References
- Harrop JS, Bailey JE, Woodhead JS. Incidence of hypercalcaemia and primary hyperparathyroidism in relation to the biochemical profile. J Clin Pathol 1982; 35(4): 395–400
- Palmer M, Jakobsson S, Å kerströ m G, et al. Prevalence of hypercalcaemia in a health survey: a 14-year follow-up study of serum calcium values. Eur J Clin Invest 1988; 18(1): 39–46
- Bilezikian JP. Etiologies and therapy of hypercalcemia. Endocrinol Metab Clin North Am 1989; 18(2): 389–414
- Stewart AF, Broadus AE. Mineral metabolism. In: Felig P, Baxter JD, Broadus AE, et al, eds. Endocrinology and metabolism. 2d ed. New York: McGraw-Hill, 1987: 1378
- Nussbaum SR, Potts JT Jr. Immunoassays for parathyroid hormone 1–84 in the diagnosis of hyperparathyroidism. J Bone Miner Res 1991; (6 Suppl 2): S43–50, S61
- Arnaud CD. Familial benign hypercalcemia: natures solution to neonatal hyperparathyroidism? (Editorial) Mayo Clin Proc 1984; 59(12): 864–5
- Levine MM, Kleeman CR. Hypercalcemia: pathophysiology and treatment. Hosp Pract (Off Ed) 1987; 22(7): 73–90
- Budayr AA, Nissenson RA, Klein RE, et al. Increased serum levels of a parathyroid hormones like protein in malignancy-associated hypercalcemia. Ann Intern Med 1989; 111(10): 807–12
- Ratcliffe WA, Hutchesson AC, Bundred NJ, et al. Role of assays for parathyroid-hormone-related protein in investigation of hypercalcaemia. Lancet 1992; 339(8786): 164–7
- Lufkin EG, DeRemee RA, Rohrbach MS. The predictive value of serum angiotensin-converting enzyme activity in the differential diagnosis of hypercalcemia. Mayo Clin Proc 1983; 58(7): 447–51
- Stewart AF, Adler M, Byers CM, et al. Calcium homeostasis in immobilization: an example of resorptive hypercalciuria. N Engl J Med 1982; 306(19): 1136–40
- Bilezikian JP. Management of acute hypercalcemia. N Engl J Med 1992; 326(18): 1196–203
- Jacobs TP, Gordon AC, Silverberg SJ, et al. Neoplastic hypercalcemia: physiologic response to intravenous etidronate disodium. Am J Med 1987; 82(2A Suppl): 42–50
- Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992; 10(1): 134–42
- Warrell RP Jr, Bockman RS, Coonley CJ, et al. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 1984; 73(5): 1487–90
- Potts JT Jr. Clinical Review 9: Management of asymptomatic hyperparathyroidism. J Clin Endocrinol Metab 1990; 70(6): 1489–93
- Marcus R, Madvig P, Crim M, et al. Conjugated estrogens in the treatment of postmenopausal women with hyperparathyroidism. Ann Intern Med 1984; 100(5): 633–40
- Scholz DA, Purnell DC. Asymptomatic primary hyperparathyroidism: 10-year prospective study. Mayo Clin Proc 1981; 56(8): 473–8
- Consensus Development Conference Panel. Diagnosis and management of asymptomatic primary hyperparathyroidism: consensus development conference statement. Ann Intern Med 1991; 114(7): 593–7
- Davies M. Primary hyperparathyroidism: aggressive or conservative treatment? Clin Endocrinol (Oxf) 1992; 36(4): 325–32
- Law WM Jr, Heath H 3d. Familial benign hypercalcemia (hypocalciuric hypercalcemia): clinical and pathogenetic studies in 21 families. Ann Intern Med 1985; 102(4): 511–9